2 results
Approved WMOCompleted
primaryTo assess the safety and tolerability of multiple, once-daily oral doses of RDN-929 over 28 days in healthy older adult subjects and early symptomatic AD subjects.secondaryTo assess the plasma and CSF pharmacokinetics (PK) of RDN-929 in…
Approved WMORecruiting
The primary objective is to evaluate and report the effect of an injected hyaluronic acid spacer on the rate of telangiectasia following PBSI.